Haemonetics Co. (NYSE:HAE) SVP Jacqueline Scanlan sold 208 shares of the stock in a transaction on Friday, June 7th. The stock was sold at an average price of $103.38, for a total value of $21,503.04. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Jacqueline Scanlan also recently made the following trade(s):

  • On Tuesday, May 14th, Jacqueline Scanlan sold 1,508 shares of Haemonetics stock. The stock was sold at an average price of $100.00, for a total value of $150,800.00.

Shares of NYSE HAE opened at $108.12 on Wednesday. The company has a current ratio of 2.44, a quick ratio of 1.62 and a debt-to-equity ratio of 0.48. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $117.56. The firm has a market capitalization of $5.31 billion, a P/E ratio of 45.24, a P/E/G ratio of 2.62 and a beta of 0.66.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 EPS for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.06. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The company had revenue of $249.30 million for the quarter, compared to analysts’ expectations of $250.62 million. During the same quarter last year, the business earned $0.43 earnings per share. Haemonetics’s revenue was up 6.7% on a year-over-year basis. As a group, equities analysts anticipate that Haemonetics Co. will post 2.93 EPS for the current year.

A number of research analysts recently commented on HAE shares. TheStreet upgraded Haemonetics from a “c+” rating to a “b-” rating in a research report on Tuesday, May 7th. Raymond James upgraded Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a research report on Tuesday, May 14th. Barrington Research restated an “outperform” rating and issued a $116.00 price target (up previously from $112.00) on shares of Haemonetics in a research report on Wednesday, May 8th. Finally, Zacks Investment Research upgraded Haemonetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $118.60.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Financial Gravity Companies Inc. acquired a new stake in Haemonetics in the fourth quarter valued at about $41,000. NumerixS Investment Technologies Inc boosted its stake in Haemonetics by 500.0% in the first quarter. NumerixS Investment Technologies Inc now owns 600 shares of the medical instruments supplier’s stock valued at $52,000 after buying an additional 500 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Haemonetics by 708.8% in the first quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 567 shares in the last quarter. Ellis Investment Partners LLC acquired a new stake in Haemonetics in the first quarter valued at about $79,000. Finally, Ffcm LLC boosted its stake in Haemonetics by 134.4% in the fourth quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock valued at $174,000 after buying an additional 1,000 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

WARNING: “Insider Selling: Haemonetics Co. (NYSE:HAE) SVP Sells 208 Shares of Stock” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://theolympiareport.com/2019/06/12/insider-selling-haemonetics-co-nysehae-svp-sells-208-shares-of-stock.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: What is the Coverage Ratio?

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.